Form 8-K · Current report
News Corp 8-K, filed Aug 12, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000178
Summary
News Corp repurchased 62,323 of its Nasdaq-listed Class A common shares for US$1,776,990.77 on 11 August 2026 under its 2025 Repurchase Program, which authorizes up to US$1 billion of Class A and Class B stock buybacks; roughly US$417.98 million has been spent under the program to date.
Key points
- News Corp is authorized to acquire up to an aggregate of US$1 billion of its Class A and Class B common stock under the 2025 Repurchase Program, authorized as of July 15, 2025.
- As of 11 August 2026, approximately US$417,978,962 in total consideration had been paid under the program.
- The 11 August 2026 buyback covered 62,323 shares at prices between US$28.39 and US$29.39.
- No ASX-listed CDIs will be repurchased under the program, and Goldman Sachs & Co. LLC is named as broker.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.